Allarity Therapeutics, Inc. (ALLR)
(Delayed Data from NSDQ)
$1.54 USD
-0.04 (-2.53%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $1.53 -0.01 (-0.65%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth A Momentum D VGM
Fundamental Charts
About Return on Equity (TTM)
Allarity Therapeutics, Inc.'s return on equity, or ROE, is -173.31% compared to the ROE of the Medical - Biomedical and Genetics industry of -66.95%. While this shows that ALLR has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
ALLR 1.54 -0.04(-2.53%)
Will ALLR be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ALLR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ALLR
Are Medical Stocks Lagging Boston Scientific (BSX) This Year?
ALLR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for ALLR
ALLR Fell Below 20 Day Moving Average on September 19
ALLR Crossed Above 20 Day Moving Average on September 18
Is ALLR building bullish momentum? 1,2,3 Pullback Bullish shows up after declining 3.29%
ALLR forms 20 Day Moving Average Support on September 16
Technical picture remains unchanged for ALLR after it falls 1.81% on September 15